EP Patent

EP2536705A1 — Polymorphic forms of lubiprostone

Assigned to Apotex Pharmachem Inc · Expires 2012-12-26 · 13y expired

What this patent protects

There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.

USPTO Abstract

There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.

Drugs covered by this patent

Patent Metadata

Patent number
EP2536705A1
Jurisdiction
EP
Classification
—
Expires
2012-12-26
Drug substance claim
No
Drug product claim
No
Assignee
Apotex Pharmachem Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.